Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.200 Biomarker disease BEFREE The objective of the present study was to determine whether immunohistochemical staining for p53 was predictive of lymph node metastases in early muscle invasive transitional cell bladder cancer. 10606186 1999
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.200 Biomarker disease BEFREE Eighty-seven transitional cell carcinoma of the bladder were analyzed by immunohistochemistry (IHC) for p53 nuclear accumulation, and the results compared to mutations detected in the p53 gene evaluated by polymerase chain reaction single-strand conformation polymorphism (SSCP) and DNA sequence analysis. 10675477 2000
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.200 Biomarker disease BEFREE Role of TP53 in repair of N-(deoxyguanosin-8-yl)-4-aminobiphenyl adducts in human transitional cell carcinoma of the urinary bladder. 11159753 2001
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.200 Biomarker disease BEFREE Molecular screening of multifocal transitional cell carcinoma of the bladder using p53 mutations as biomarkers. 9816132 1996
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.200 Biomarker disease BEFREE Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder. 8627878 1996
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.200 Biomarker disease BEFREE In the present study we correlate the p53 gene mutations in tumour tissue with urine sediment using a functional assay in yeast, and relate the p53 status to the outcome in a group of patients with transitional cell carcinoma of the bladder. 15308588 2004
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.200 Biomarker disease BEFREE Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma. 21388952 2011
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.200 Biomarker disease BEFREE Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder. 18645275 2008
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.200 Biomarker disease HPO
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.200 Biomarker disease BEFREE A comparative gene set enrichment analysis of tumor and adjacent normal tissues suggested BUC tumorigenesis resulted mainly from enrichment of cell cycle and DNA damage and repair-related biological processes and pathways, including TP53 and mitotic recombination. 28356754 2017
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.200 Biomarker disease BEFREE Tumor-associated angiogenesis adds additional useful prognostic information to that which is obtained from p53 status in patients with invasive transitional cell carcinoma of the bladder. 9815851 1997
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.200 AlteredExpression disease BEFREE Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. 8428790 1993
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.200 AlteredExpression disease BEFREE The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy. 9891547 1999
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.200 AlteredExpression disease BEFREE We analyzed the relationship between p53 protein expression in bladder cancer tissue, p53 autoantibodies in serum and the clinical course of 32 patients with and 10 patients without transitional cell carcinoma of the urinary bladder. 10782026 2000
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.200 AlteredExpression disease BEFREE To investigate the overexpression of p53 oncoprotein in transitional-cell carcinoma of the bladder, 58 bladder cancer specimens of different clinical stages and histological grades were investigated using an immunohistochemical approach. 7881474 1994
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.200 AlteredExpression disease BEFREE Significance of p53 overexpression in urinary bladder transitional cell carcinoma in situ before and after bacillus Calmette-Guérin treatment. 9111623 1997
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.200 AlteredExpression disease BEFREE In immunohistochemical studies of bladder tumor tissue, over expression of p53 protein was detected with antibody pAb1801 and loss of Rb protein expression was evaluated with antibody PMG3-245 in patients with transitional cell carcinoma of the bladder. 8640913 1996
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.200 AlteredExpression disease BEFREE BAI‑1 may be involved in the negative regulation of BTCC microvascular proliferation, and its expression may be associated with a reduction in p53 mutations. 26129954 2015
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.200 AlteredExpression disease BEFREE DNA ploidy and p53 protein expression in superficial transitional cell carcinoma of the bladder. 10772009 2000
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.200 AlteredExpression disease BEFREE Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder. 10940702 2000
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.200 AlteredExpression disease BEFREE Our aim was to investigate the expression of p53 oncoprotein in superficial and invasive transitional cell bladder cancer (TCC) as well as its correlation with established prognostic factors, such as histologic grade, tumor stage, DNA content, and survival. 7660508 1995
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.200 AlteredExpression disease BEFREE Assessment of the transcriptional activity of p53 improves the prediction of recurrence in superficial transitional cell carcinoma of the bladder. 16000567 2005
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.200 AlteredExpression disease BEFREE Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. 7677935 1993
Entrez Id: 7157
Gene Symbol: TP53
TP53
0.200 AlteredExpression disease BEFREE Nuclear p53 overexpression occurred in 18.2% of transitional cell bladder cancer specimens, 12.2% of prostate cancer specimens, and 17.9% of renal cell cancer specimens. 9477181 1997